Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
News|Articles|October 24, 2019
AptarGroup Receives FDA Approval for Packaging Solution for HIV Prevention Medicine
Author(s)Pharmaceutical Technology Editors
The packaging solution works to protect drugs with a 3-Phase Activ-Polymer solution, a technology that is customized for the drug developer’s formulation, offers a broad spectrum of specific drug protection, and oxygen and odor scavenging.
Advertisement
AptarGroup, a consumer dispensing, active packaging, and drug delivery solutions company headquartered in Crystal Lake, IL, announced its packaging solution for oral-solid-dose drug delivery, Activ-Blister, was approved by FDA for an HIV prevention medicine.
The packaging solution works to protect drugs with a 3-Phase Activ-Polymer solution, a technology that is customized for the drug developer’s formulation, offers a broad spectrum of specific drug protection, and oxygen and odor scavenging, according to an Oct. 22, 2019 press release. With the ability to maintain this technology, the Activ-Blister helps biotech and pharmaceutical companies meet long-term and in-use stability drug requirements.
“I am very pleased to announce this recent FDA approval of our proprietary Activ-Blister technology,” said Stephan Tanda, Aptar’s president and CEO, in the press release. “This is a significant step that further validates the expanding portfolio of solutions offered by Aptar CSP Technologies. We will continue to leverage our proprietary 3-Phase Activ-Polymer technology to help our customers with unique protective formulations that de-risk their drug development process and help strengthen their own offerings. The ultimate result is that we are creating meaningful solutions that help improve and save lives.”
Aptar will be exhibiting at Stand 111D70 at CPhI Worldwide from Nov. 5–7 in Frankfurt, Germany.
Source:
Advertisement
Related to this article
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Advertisement
Advertisement